Satraplatin

N/A

Report date: 2026/01/13 20:00:24
NME

Base Information

Drug NameSatraplatin
Drug Alias Namesatraplatino沙铂赛特铂satraplatinesatraplatinum +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA cross linking agentsDNA synthesis inhibitors
TargetsDNA
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerHormone-Resistant Prostate Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[18] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGpc Biotech
China Registration ClassN/A

Develop Information

Active CompaniesPharmaand GmbHShanghai Jiao Tong University School of Medicine
Inactive CompaniesAgennixYale UniversityNational Cancer Institute
Active IndicationsProstatic Neoplasms
Inactive IndicationsBrain metastasesMetastatic breast cancerHormone-Resistant Prostate Neoplasms +[8] 

Other Information

ATC CodeL01XA04
Related LinksWikipediaDrugBankKEGG